

Chronic Pancreatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C8CFC9047F9EEN.html>

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: C8CFC9047F9EEN

Abstracts

The 7 major chronic pancreatitis markets reached a value of US\$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.49% during 2024-2034.

The chronic pancreatitis market has been comprehensively analyzed in IMARC's new report titled "Chronic Pancreatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic pancreatitis refers to long-term inflammation of the pancreas, a gland located behind the stomach. It is often characterized by the destruction and scarring of pancreatic tissue. Over time, this condition can impair the normal functioning of the pancreas, affecting its ability to produce digestive enzymes and hormones. The common symptoms associated with the ailment include pain in the upper abdomen, diarrhea, fatty, loose and pale stools, nausea, vomiting, shortness of breath, unexplained weight loss, excessive thirst, fatigue, etc. In severe cases, individuals suffering from this disease may also experience a yellowish discoloration in the eyes and skin, pancreatic fluids in the abdomen, internal bleeding, intestinal blockage, etc. The diagnosis of chronic pancreatitis typically involves a review of the patient's underlying symptoms, medical history, and imaging studies. Numerous procedures, including X-rays, ultrasounds, computed tomography scans, magnetic resonance imaging, etc., are adopted to identify abnormalities in the abdomen or check for any signs of inflammation in patients. The healthcare provider may also perform an endoscopy to directly visualize the condition of the pancreas and confirm a diagnosis.

The increasing incidence of prolonged and excessive alcohol intake, which can lead to inflammation and damage to the pancreas, is primarily driving the chronic pancreatitis

market. Apart from this, the rising prevalence of gallstones, which can cause blockages in the pancreatic duct and prevent the normal flow of digestive enzymes, is also augmenting the market growth. Moreover, the widespread utilization of nonsteroidal anti-inflammatory drugs, opioids, analgesics, etc., for treating the disease, since they help in reducing the pain associated with the condition, is further creating a positive outlook for the market. Besides this, the inflating application of enzyme replacement therapy to significantly improve digestion and nutrient absorption in patients is also propelling the market growth. Furthermore, the escalating utilization of endoscopic retrograde cholangiopancreatography techniques that combine endoscopy and fluoroscopy to diagnose and treat conditions of the pancreatic duct is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal shock wave lithotripsy, a non-invasive procedure that uses shock waves to break down gallstones or pancreatic stones, thereby normalizing the functions of the pancreas, is expected to drive the chronic pancreatitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic pancreatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic pancreatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic pancreatitis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the chronic pancreatitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the chronic pancreatitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic pancreatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Chronic Pancreatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 202...

Market Insights

How has the chronic pancreatitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the chronic pancreatitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the chronic pancreatitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of chronic pancreatitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of chronic pancreatitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of chronic pancreatitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with chronic pancreatitis across the seven major markets?

What is the size of the chronic pancreatitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of chronic pancreatitis?

What will be the growth rate of patients across the seven major markets?

Chronic Pancreatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for chronic pancreatitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic pancreatitis market?

What are the key regulatory events related to the chronic pancreatitis market?

What is the structure of clinical trial landscape by status related to the chronic pancreatitis market?

What is the structure of clinical trial landscape by phase related to the chronic pancreatitis market?

What is the structure of clinical trial landscape by route of administration related to the chronic pancreatitis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CHRONIC PANCREATITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 CHRONIC PANCREATITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CHRONIC PANCREATITIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 CHRONIC PANCREATITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 CHRONIC PANCREATITIS - UNMET NEEDS

10 CHRONIC PANCREATITIS - KEY ENDPOINTS OF TREATMENT

11 CHRONIC PANCREATITIS - MARKETED PRODUCTS

- 11.1 List of Chronic Pancreatitis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Clinical Trial Results
 - 11.1.1.4 Safety and Efficacy
 - 11.1.1.5 Regulatory Status

Kindly note that the complete list of marketed drugs has been provided in the report.

12 CHRONIC PANCREATITIS - PIPELINE DRUGS

12.1 List of Chronic Pancreatitis Pipeline Drugs Across the Top 7 Markets

12.1.1 NI03 - Kangen Pharmaceuticals, Inc

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 MS1819 SD- First Wave BioPharma/Mayoly-Spindler

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 CM6018 - CalciMedica

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. CHRONIC PANCREATITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. CHRONIC PANCREATITIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 CHRONIC PANCREATITIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Chronic Pancreatitis - Market Size

- 15.2.1.1 Market Size (2018-2023)
- 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Chronic Pancreatitis - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Chronic Pancreatitis - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Chronic Pancreatitis - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Chronic Pancreatitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Chronic Pancreatitis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Chronic Pancreatitis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Chronic Pancreatitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Chronic Pancreatitis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Chronic Pancreatitis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Chronic Pancreatitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Chronic Pancreatitis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Chronic Pancreatitis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Chronic Pancreatitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Chronic Pancreatitis - Market Size

- 15.7.1.1 Market Size (2018-2023)
- 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Chronic Pancreatitis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Chronic Pancreatitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Chronic Pancreatitis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Chronic Pancreatitis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Chronic Pancreatitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Chronic Pancreatitis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Chronic Pancreatitis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Chronic Pancreatitis - Access and Reimbursement Overview

16 CHRONIC PANCREATITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CHRONIC PANCREATITIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 CHRONIC PANCREATITIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Chronic Pancreatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C8CFC9047F9EEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8CFC9047F9EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

